There are two vaccines for HPV. The first to be approved was Gardasil, a vaccine aimed at HPV types 6, 11, 16, and 18. HPV types 16 and 18 cause over 70 percent of cervical cancer, while HPV types
6 and 11 are responsible for over 90 percent of genital warts. It is recommended for girls and women ages nine to twenty-six and is given in a series of three doses. The second dose is given two months after the first dose, and the final dose is given four months after the second dose.
The second HPV vaccine is called Cervarix. It has been approved in Europe and Australia, but approval in the United States is not expected until 2009. Cervarix only protects against HPV types 16 and 18, although cross protection against types 31 and 45 has been seen in one study. It is also a three-dose series but is given at zero months, one month, and six months. Cervarix is recommended for all girls and women ages ten to forty-five.